美国神经外科医师大会系统综述与循证指南:化疗在新诊断成人WHO II级弥漫性胶质瘤中的作用(更新版)
该指南由美国神经外科医师大会基于系统综述制定,针对成人新诊断WHO II级弥漫性胶质瘤,就化疗作为辅助治疗的角色、受益人群、肿瘤标志物、启动时机、药物方案、疗程剂量及与放疗联合等问题给出推荐等级(I–III级)或指出证据不足。
要点
- III级推荐:化疗可作为推迟放疗、延缓肿瘤生长、改善无进展生存期(PFS)、总生存期(OS)和临床症状的治疗选择。
- I级推荐:高危WHO II级弥漫性胶质瘤患者(<40岁未能全切及>40岁无论切除程度)在放疗基础上加用PCV化疗以改善OS。
- III级推荐:IDH突变患者放疗基础上加化疗;1p/19q共缺失患者可考虑单用化疗(替莫唑胺)。
核心结论
- 化疗可作为成人新诊断WHO II级弥漫性胶质瘤的辅助治疗选择,可推迟放疗、延缓肿瘤生长并改善PFS、OS和临床症状(III级推荐)。
- 高危患者(<40岁未能全切及>40岁无论切除程度)推荐在放疗基础上加用PCV化疗以改善OS(I级推荐)。
- IDH突变患者推荐放疗基础上加化疗(III级推荐);1p/19q共缺失患者建议考虑单用化疗(III级推荐)。
- 新辅助替莫唑胺可用于因浸润 eloquent 区或对侧广泛延伸而不宜手术的WHO II级弥漫性胶质瘤患者,作为提高切除程度的初始步骤(III级推荐)。
研究设计与样本
- 美国神经外科医师大会(Congress of Neurological Surgeons)基于系统综述制定的循证指南更新版。
- 目标人群为年龄大于18岁、新诊断WHO II级胶质瘤(少突胶质细胞瘤、星形细胞瘤、混合性少突星形细胞瘤)的成人患者。
主要发现
- 化疗推荐作为治疗选择以推迟放疗、延缓肿瘤生长、改善PFS、OS和临床症状(III级推荐)。
- 无法全切的新诊断LGG患者,化疗可单独或联合放疗作为初始辅助治疗;术后MRI残留肿瘤>1 cm、就诊直径4 cm或年龄>40岁患者也应考虑辅助治疗(III级推荐)。
- IDH突变患者推荐放疗基础上加化疗;1p/19q共缺失患者推荐替莫唑胺作为延缓肿瘤生长的治疗选择(III级推荐)。
- 高危WHO II级弥漫性胶质瘤患者放疗加PCV化疗可改善OS(I级推荐);放疗加化疗改善OS且不降低神经认知功能(II级推荐);放疗加替莫唑胺改善PFS和OS(III级推荐)。
关键数值与推荐
- Level III:化疗推荐作为推迟放疗、延缓肿瘤生长、改善PFS、OS和临床症状的治疗选择。
- Level III:化疗推荐作为无法全切患者单独或联合放疗的初始辅助治疗可选组成部分;术后MRI残留>1 cm、就诊直径4 cm或年龄>40岁也应考虑辅助治疗。
- Level III:IDH突变患者推荐放疗基础上加化疗;1p/19q共缺失患者推荐替莫唑胺作为延缓肿瘤生长的治疗选择。
- Level I:高危WHO II级弥漫性胶质瘤(<40岁未能全切及>40岁无论切除程度)推荐放疗加PCV化疗以改善OS;Level II:放疗加化疗改善OS且不降低神经认知功能;Level III:放疗加替莫唑胺改善PFS和OS;Level III:1p/19q共缺失患者建议考虑单用化疗。
- Level III:新辅助替莫唑胺可用于因浸润 eloquent 区或对侧广泛延伸而不宜手术的WHO II级弥漫性胶质瘤患者,作为提高切除程度的初始步骤;关于新辅助化疗改善PFS和OS的证据不足。
临床怎么用
- 化疗可作为成人新诊断LGG的辅助治疗选择,以推迟放疗、延缓肿瘤生长、改善PFS、OS和临床症状(III级推荐)。
- 无法全切的患者可考虑化疗单独或联合放疗作为初始辅助治疗;术后MRI残留>1 cm、就诊直径4 cm或年龄>40岁也应考虑辅助治疗(III级推荐)。
- IDH突变患者推荐放疗基础上加化疗;1p/19q共缺失患者推荐替莫唑胺(III级推荐)。
- 高危患者(<40岁未能全切及>40岁无论切除程度)推荐放疗加PCV化疗以改善OS(I级推荐)。
- 新辅助替莫唑胺可用于因浸润 eloquent 区或对侧广泛延伸而不宜手术的患者,作为提高切除程度的初始步骤(III级推荐)。
局限性
- 关于化疗启动时机,证据不足以做出明确推荐;建议以12周作为启动辅助化疗的最晚时间框架,并推荐患者入组设计良好的临床试验。
- 关于化疗药物方案选择,证据不足以推荐某一特定方案;推荐入组比较不同方案疗效的临床试验。
- 关于化疗疗程和剂量,证据不足以就任何特定细胞毒药物方案的疗程做出推荐;推荐入组评估最佳疗程的临床研究。
- 关于化疗单独还是联合放疗作为初始治疗,证据不足;推荐入组比较化疗单独、放疗单独或联合治疗的临床试验。
- 关于新辅助化疗改善PFS和OS、替莫唑胺增加恶性转化风险、多药化疗对比单药化疗改善PFS和OS,证据均不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Questions and recommendations from the prior version of these guidelines without changeTarget populationAdult patients (older than 18 years of age) with newly diagnosed World Health Organization (WHO) Grade II gliomas (Oligodendroglioma, astrocytoma, mixed oligoastrocytoma).QuestionIs there a role for chemotherapy as adjuvant therapy of choice in treatment of patients with newly diagnosed low-grade gliomas?RecommendationLevel III: Chemotherapy is recommended as a treatment option to postpone the use of radiotherapy, to slow tumor growth and to improve progression free survival (PFS), overall survival (OS) and clinical symptoms in adult patients with newly diagnosed LGG.QuestionWho are the patients with newly diagnosed LGG that would benefit the most from chemotherapy?RecommendationLevel III: Chemotherapy is recommended as an optional component alone or in combination with radiation as the initial adjuvant therapy for all patients who cannot undergo gross total resection (GTR) of a newly diagnosed LGG. Patients with residual tumor >1 cm on post-operative MRI, presenting diameter of 4 cm or older than 40 years of age should be considered for adjuvant therapy as well.QuestionAre there tumor markers that can predict which patients can benefit the most from initial treatment with chemotherapy?RecommendationLevel III: The addition of chemotherapy to standard RT is recommended in LGG patients that carry IDH mutation. In addition, temozolomide (TMZ) is recommended as a treatment option to slow tumor growth in patients who harbor the 1p/19q co-deletion.QuestionHow soon should the chemotherapy be started once the diagnosis of LGG is confirmed?RecommendationThere is insufficient evidence to make a definitive recommendation on the timing of starting chemotherapy after surgical/pathological diagnosis of LGG has been made. However, using the 12 weeks mark as the latest timeframe to start adjuvant chemotherapy is suggested. It is recommended that patients be enrolled in properly designed clinical trials to assess the timing of chemotherapy initiation once diagnosis is confirmed for this target population.QuestionWhat chemotherapeutic agents should be used for treatment of newly diagnosed LGG?RecommendationThere is insufficient evidence to make a recommendation of one particular regimen. Enrollment of subjects in properly designed trials comparing the efficacy of these or other agents is recommended so as to determine which of these regimens is superior.QuestionWhat is the optimal duration and dosing of chemotherapy as initial treatment for LGG?RecommendationInsufficient evidence exists regarding the duration of any specific cytotoxic drug regimen for treatment of newly diagnosed LGG. Enrollment of subjects in properly designed clinical investigations assessing the optimal duration of this therapy is recommended.QuestionShould chemotherapy be given alone or in conjunction with RT as initial therapy for LGG?RecommendationInsufficient evidence exists to make recommendations in this regard. Hence, enrollment of patients in properly designed clinical trials assessing the difference between chemotherapy alone, RT alone or a combination of them is recommended.QuestionShould chemotherapy be given in addition to other type of adjuvant therapy to patients with newly diagnosed LGG?RecommendationLevel II: It is recommended that chemotherapy be added to the RT in patients with unfavorable LGG to improve their progression free survival.Updated Question and Recommendations from the Prior Version of These GuidelinesQuestionIn adult patients with pathologically confirmed WHO Grade II diffuse glioma does chemotherapy alone, combined with radiation therapy or after radiation therapy compared to radiotherapy alone result in better overall survival, progression free survival, local control, fewer complications, neurocognitive preservation, and quality of life?RecommendationLevel I: It is recommended that chemotherapy (PCV) be added to radiation therapy (RT) in all patients with newly diagnosed high-risk WHO Grade II diffuse glioma (Patients younger than 40 unable to get gross total resection and older than 40 regardless of the degree of resection) to improve their overall survival. LEVEL II: It is recommended that chemotherapy be added to radiation therapy in all patients with newly diagnosed high-risk WHO Grade II diffuse glioma to improve overall survival without a decline in neurocognitive function. LEVEL III: It is suggested that chemotherapy (temozolomide) be added to RT in all patients with newly diagnosed high-risk WHO Grade II diffuse glioma to improve progression free survival and overall survival. LEVEL III: It is suggested that chemotherapy alone should be considered in patients with newly diagnosed WHO Grade II diffuse glioma in cases with 1p/19q co-deletion.New questions and recommendationsTarget populationThese recommendations apply to adult patients diagnosed with WHO Grade II diffuse glioma.QuestionIn adult patients with newly diagnosed WHO grade II diffuse glioma does administration of chemotherapy prior to surgical resection improve extent of resection, provide longer progression free survival and overall survival when compared to chemotherapy alone?RecommendationLevel III: Neo-adjuvant temozolomide may be used in patients with WHO Grade II diffuse gliomas deemed unsafe for resection due to infiltration of eloquent areas or with large contralateral extension as an initial step to improve the extent of resection.There is insufficient evidence to support a recommendation regarding the ability of chemotherapy provided prior to surgical resection to improve progression free survival (PFS) and overall survival (OS).QuestionIn adult patients with newly diagnosed WHO grade II diffuse glioma does the administration of temozolomide increase the rate of malignant transformation when compared to no chemotherapy or other chemotherapy regimens?RecommendationThere is insufficient evidence to support a recommendation against the use of temozolomide for WHO Grade II diffuse gliomas due to concern over increasing the rate of malignant transformation.QuestionIn adult patients with newly diagnosed WHO grade II diffuse glioma does administration of multi-agent chemotherapy improve progression free survival and overall survival when compared to administration of single-agent chemotherapy?RecommendationThere is insufficient evidence to support a recommendation for or against the use of multi-agent chemotherapy to improve progression free survival and overall survival when compared to administration of single-agent chemotherapy in patients with newly diagnosed WHO Grade II diffuse glioma.
引用
- Ziu M, Halasz LM, Kumthekar PU, et al. Congress of Neurological Surgeons systematic review and evidence-based guidelines for the role of chemotherapy in newly diagnosed WHO Grade II diffuse glioma in adults: update. J Neurooncol. 2024. PMID: 39565459. doi:10.1007/s11060-024-04861-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。